Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Official title

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer

Study identification

NCT ID

NCT05624996

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 3

Lead sponsor

NRG Oncology

Other

Enrollment

474 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years and older

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Jul 11, 2023

Primary completion

Oct 14, 2031

Completion

Oct 14, 2031

Last update posted

May 3, 2026

2023 – 2031

United States locations

U.S. sites

470

U.S. states

43

U.S. cities

355

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.